NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study)

• DOI: 10.1161/strokeaha.116.014644
• Publication Date: 2016-12-16T04:48:14Z
• Authors: Aliona Nacu; Christopher E. Kv...; Halvor Naess; Halvor Øygarden; Nicola Logallo; Jörg Assmus; Ulrike Waje-Andre...; Kathinka D. Kurz; Gesche Neckelmann; Lars Thomassen
• Keywords: Stroke

The NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study) aimed to assess effect and safety of contrast-enhanced ultrasound treatment an unselected acute ischemic stroke population.Patients treated with intravenous thrombolysis within 4.5 hours after symptom onset were randomized 1:1 either sonothrombolysis (CEST) or sham CEST. A visible arterial occlusion on baseline computed tomography angiography was not a prerequisite for inclusion. Pulse-wave 2 MHz given 1 hour contrast (SonoVue) as infusion ≈30 minutes. Magnetic resonance imaging performed 24 36 hours. Primary study end points neurological improvement at defined National Institutes Health Scale score 0 reduction ≥4 compared favorable functional outcome 90 days modified Rankin scale 1.A total 183 patients randomly assigned CEST (93 patient) (90 patients). rates symptomatic intracerebral hemorrhage, asymptomatic mortality increased the group. Neurological similar groups both intention-to-treat analysis per-protocol analysis.CEST is safe among without varying grades clinical severity. There was, however, statistically no significant this prematurely stopped trial.URL: http://www.clinicaltrials.gov. Unique identifier: NCT01949961.